# Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.

> **NCT04835064** · PHASE3 · UNKNOWN · sponsor: **Fudan University** · enrollment: 600 (estimated)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Nab paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** mFOLFIRINOX

## Key facts

- **NCT ID:** NCT04835064
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-12-01
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04835064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04835064, "Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04835064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*